


N-(Azido-PEG4)-biocytin

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-140919 | | |
| CAS No.: | 2055042-70-9 | | |
| Molecular Formula: | C ₂₇ H ₄₇ N ₇ O ₉ S | | |
| Molecular Weight: | 645.77 | | |
| Target: | PROTAC Linkers | | |
| Pathway: | PROTAC | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|---|
| Description | N-(Azido-PEG4)-biocytin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs ^[1] . N-(Azido-PEG4)-biocytin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups. |
| IC₅₀ & Target | PEGs |
| In Vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA